Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARCT
ARCT logo

ARCT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Arcturus Therapeutics Holdings Inc (ARCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.530
1 Day change
2.31%
52 Week Range
24.170
Analysis Updated At
2026/06/18
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Arcturus Therapeutics Holdings Inc (ARCT) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators show a mixed trend, with bearish moving averages and neutral RSI. Options data suggests a lack of strong bullish sentiment, and there are no significant news or catalysts to drive the stock higher. Additionally, there is no recent Congress trading data or financial performance insights available to support a buy decision. Given the lack of strong positive signals and the investor's preference for long-term stability, holding off on this stock is the most prudent choice.

Technical Analysis

The MACD histogram is positive and expanding, suggesting a slight bullish momentum. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. RSI is neutral at 60.771, and the stock is trading near its pivot level of 7.302, with resistance at 7.803 and support at 6.802.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The implied volatility (IV) is high at 91.94, with an IV percentile of 84.92, indicating elevated uncertainty. The put-call ratios suggest a slight bullish sentiment, but the low volume (28 contracts traded today) indicates limited activity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
6
Buy
4

Positive Catalysts

  • The MACD histogram is positive and expanding, which could indicate a short-term bullish momentum.

Neutral/Negative Catalysts

  • Bearish moving averages, lack of significant news or catalysts, no recent Congress trading data, and limited options activity.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes provided for ARCT.

Wall Street analysts forecast ARCT stock price to rise
4 Analyst Rating
Wall Street analysts forecast ARCT stock price to rise
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 7.360
sliders
Low
7
Averages
14
High
20
Current: 7.360
sliders
Low
7
Averages
14
High
20
B. Riley
Buy
initiated
$22
AI Analysis
2026-03-18
Reason
B. Riley
Price Target
$22
AI Analysis
2026-03-18
initiated
Buy
Reason
B. Riley initiated coverage of Arcturus Therapeutics with a Buy rating and $22 price target. The firm says the company "stands out" given its lipid-enabled and unlocked nucleic acid modified RNA platform. The platform enables multi-tissue, safe, efficient, and effective delivery of messenger RNA that is applied to two wholly-owned rare disease programs, inhaled ARCT-032 for cystic fibrosis and intravenously administered ARCT-810 for ornithine transcarbamylase, the analyst tells investors in a research note.
Canaccord
Whitney Ijem
Buy
downgrade
$66 -> $21
2026-03-05
Reason
Canaccord
Whitney Ijem
Price Target
$66 -> $21
2026-03-05
downgrade
Buy
Reason
Canaccord analyst Whitney Ijem lowered the firm's price target on Arcturus Therapeutics to $21 from $66 and keeps a Buy rating on the shares. The firm updated its model following uneventful Q4 results as execution continues to be up and down and as a result the analyst adjusted thigs more conervatively than in the past. The adjustments adjustments still leave it with a valuation significantly above where shares currently trade, and as a result remain Buy rated.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARCT
Unlock Now

People Also Watch